COLUMBUS, Ohio - Pelotonia has announced record fundraising of more than $19 million for its 2013 ride.
From August 10-11, 2013, 6,723 riders and more than 2,300 volunteers from 41 states and nine countries rode up to 180 miles on one of four routes.
In partnership with Pelotonia’s sponsors, 100 percent of every rider-raised dollar through Pelotonia directly funds research at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James). Funds are allocated to four primary areas: a fellowship program, funding student researchers, “Idea Grants” that fund teams of researchers and recruitment and retention of leading cancer researchers and programs.
“To exceed $19 million in fundraising for our fifth ride is simply remarkable. Looking forward, we are on our way to generating more than $20 million annually,” Thomas Lennox, chief executive officer of Pelotonia said. “As a cancer survivor, I couldn’t be more grateful for the selfless initiative taken by our riders and volunteers toward ending cancer. I am proud to lead a group of dedicated associates who are determined to provide an exceptional Rider experience that has enabled Pelotonia to raise over $61 million in five years for Ohio State’s cancer program.”
Break-through cancer research funded by Pelotonia includes discoveries with an experimental drug called ibrutinib. The drug, developed by Pharmacyclics Inc., has potential as a safe and effective treatment alternative, with better outcomes and fewer side effects, for patients diagnosed with chronicle lymphocytic leukemia (CLL) and mantel cell lymphoma (MCL).
“Every year, I am humbled by the generosity and tenacious commitment of the thousands and thousands of Pelotonia riders and volunteers working to help us reach our goal of creating a cancer-free word,” says Michael Caligiuri, MD, director of The Ohio State University Comprehensive Cancer Center and chief executive officer of the Arthur G. James Cancer Hospital & Richard J. Solove Research Institute. “Pelotonia support has been integral to our ability to attract, support and retain brilliant clinician-scientists to Ohio State; support student and fellowship training in cancer research; purchase sophisticated research equipment critical to conducting cancer research; and funding the new big ideas in cancer research that will help us better understand the molecules and markers fueling each person’s unique cancer.”
The 2014 Pelotonia ride is scheduled for August 8-10, 2014. Rider registration will open on Jan. 7, 2014, at www.pelotonia.org.
About The OSUCCC – James
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only four in the United States funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 228-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top cancer hospitals in the nation as ranked by U.S.News & World Report.
Founded in 2008, Pelotonia was established with the objective to fund life-saving cancer research. Pelotonia is a three-day experience that includes a weekend of cycling, entertainment and volunteerism. In its first five rides, Pelotonia has raised $61 million for cancer research. Thanks to its generous sponsors, Huntington Bank, Limited Brands Foundation, Richard and Peggy Santulli, American Electric Power Foundation, Nationwide Insurance, Cardinal Health Foundation, JP Morgan Chase and The Scotts Miracle-Gro Company, Pelotonia is able to direct 100 percent of every rider-raised dollar to cancer research at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Media Contact: For more information, contact Amanda J. Harper, director of media relations at The OSUCCC – James at 614-293-3737 (central media line), 614-685-5420 (direct) or Amanda.email@example.com.